Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)
Clinical trial NCT03264989 · COMPLETED
Trial details
- NCT number
- NCT03264989
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-19
- Primary completion
- 2023-06-26
- Enrollment
- 57
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.